Genzyme Appoints New President Of Global Manufacturing, Corporate Operations

Published: 03-Feb-2010

Genzyme has appointed Scott Canute as the president of global manufacturing and corporate operations for the company. Mr Canute will oversee the production of a diverse range of products manufactured at 17 sites around the world. He has worked as the former manufacturing head in Eli Lilly.

Henri Termeer, chairman and chief executive officer at Genzyme, said: “Scott Canute is among the very top people in the pharmaceutical manufacturing field. He is widely respected for transforming manufacturing operations at Lilly and establishing its programs as a standard for the industry. His experience will accelerate efforts to strengthen our manufacturing sites, and consistently meet standards. I look forward to helping the company achieve the manufacturing capabilities that are necessary to fully serve the patients that depend on our products - both now and in the future.”

Earlier, Genzyme has also announced the appointment of Ron Branning, as senior vice president of Global Product Quality for the company. The company said that the hiring of new leadership in Manufacturing and Quality is part of Genzyme’s comprehensive plan to strengthen its global manufacturing operations.

Mr Canute held progressively responsible positions at Lilly, ultimately becoming President of Global Manufacturing Operations. In this role, he directed all manufacturing and supply chain activities for the company’s operations, which spanned 24 global manufacturing sites and more than 80 contract manufacturing operations.

Furthermore, he oversaw operations that included more than 14,000 employees, and that supplied product to more than 140 countries. He also has experience with a variety of technologies, including biologics, small and large molecules, and devices.

Mr Canute holds a degree in chemical engineering from the University of Michigan, and a masters in business administration from Harvard Business School. He was also a National Association of Manufacturers board member. In 2007, he left Lilly to pursue educational interests in business leadership and ethics.

Tell your friend about this article